Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Post Partum Hemorrhage

In brief

The goal of this study is to compare 2 medications that are commonly used to prevent excess uterine bleeding (postpartum hemorrhage, or PPH) following cesarean delivery (CD), oxytocin and carbetocin. Most of the trials evaluating the preventative role of oxytocin and carbetocin after CD have focused on patient with low-risk of PPH. This trial will focus on patients that are at increased risk of PPH, with risk factors such as: multiple gestation (twins, or more multiples), large baby, polyhydramnios (excess amniotic fluid), history of PPH, body mass index greater than 40, diabetes mellitus, hypertension, and placenta previa. The investigators hypothesize that carbetocin would be more effective than an oxytocin regimen in reducing the risk of PPH in patients undergoing CD with any of the biological high-risk factors.

Key facts

Study ID

NCT06333340

Run by

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

People needed

160

Starts

2025-01-14

Expected to finish

2026-12-01

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: accepted.

You may not qualify if…

• Valvular heart disease, arrhythmias, or heart failure
• Placenta accreta spectrum
• Bleeding disorder
• Anemia (<100 g/dl)
• Allergy or sensitivity to oxytocin or carbetocin

Where it is running

• Mount Sinai Hospital — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.